Biotech market spotlight: Mesoblast
Monday, 09 November, 2009
Regenerative medicine company, Mesoblast (ASX:MSB), has seen some fluctuating share prices over the past week, with it lifting 9.4% since last Monday's open, although it's down 3.3% in today's trading.
On Friday the company announced the latest in a series of successful trials of its stem cell treatments targeted at regenerating and repairing bone and cartilage.
The technology uses mesenchymal precursor cells (MPC), which are a form of adult stem cell that can generate new bone, cartilage, and blood vessels.
Friday's announcement concerned a study involving 18 patients who received bone marrow transplants using umbilical cord blood expanded by MPCs. These patients experienced faster recovery times and lower rates of graft-versus-host disease.
Mesoblast is currently at $1.16, down 4c or 3.33% at the close of trading on Monday evening.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
